Coala-Life and Asahi Kasei enter Technology Partnership in Japan

Stockholm, January 7, 2020 – Swedish digital health company Coala Life today announced a research and development partnership with Asahi Kasei Corporation in Japan. The collaboration includes a development program and feasibility research targeting Heart Failure (HF) patients in Japan.

Nearly one million patients are suffering from Heart Failure (HF) in Japan. The country also has the highest proportion of older people in the world resulting in substantially longer hospitalization stays and higher costs related to HF as compared to other Western and Asian countries.

Coala Life has partnered with Asahi Kasei Corporation exclusively on the Japanese market to further develop and evaluate the use of the Coala Heart Monitor for remote monitoring and management of patients affected by HF. The device is not approved in Japan, only used for research. The intent is to develop and evaluate novel digital biomarkers of HF and evaluate the clinical solutions in terms of service feasibility in Japan.

Asahi Kasei Corporation is a leading Japanese life science and industry conglomerate with approximately 40,000 employees and a group turnover of nearly SEK 200 billion.

- We’re delighted to initiate a collaboration with Asahi Kasei to further explore the unique opportunities of our digital platform and its use in helping to remotely monitor and manage Heart Failure patients, comments Dan Pitulia, CEO of Coala Life.

Heart Failure has become a public health burden globally because of the associated high morbidity and costs. Approximately 26 million adults are living with HF worldwide, and the prevalence increases with age, accounting for 12% of elderly people over 80 years old.

The financial terms of the collaboration are not disclosed.

For more info:

Dan Pitulia, CEO Coala Life AB, +46 70 972 08 38, dan.pitulia@coalalife.com